tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2026 Dec;22(1):2620849.
doi: 10.1080/21645515.2026.2620849. Epub 2026 Feb 2.
No fault vaccine injury compensation after COVID-19: A systematic literature review and proposed typology
Sam Halabi[SUP] 1 [/SUP], Nishtha Arora[SUP] 1 [/SUP], Alison Durran[SUP] 2 [/SUP], Qianhan Qian[SUP] 1 [/SUP], Shabna Ummer[SUP] 1 [/SUP], Katherine Ginsbach[SUP] 1 [/SUP], Kashish Aneja[SUP] 1 [/SUP]
Affiliations
The COVID-19 pandemic brought about a unique and rapid period of global vaccine innovation. It revealed structural challenges not only in global vaccine affordability and distribution but in the liability and indemnity structures that can both impede access and affect fair outcomes for the small number of people who suffer severe side effects. This review examines vaccine injury and compensation mechanisms, including no-fault compensation schemes, aimed at addressing both the liability and indemnity concerns of developers and the compensation due those suffering severe side effects. The ultimate aim of the review is to provide a classification of systems for those countries that are considering adopting NFCS as part of their broader public health readiness and preparedness strategies.
Keywords: COVID-19; GAVI COVAX AMC; global health governance; liability; no-fault compensation schemes (NFCS); vaccine indemnity; vaccine injury; vaccine innovation.
. 2026 Dec;22(1):2620849.
doi: 10.1080/21645515.2026.2620849. Epub 2026 Feb 2.
No fault vaccine injury compensation after COVID-19: A systematic literature review and proposed typology
Sam Halabi[SUP] 1 [/SUP], Nishtha Arora[SUP] 1 [/SUP], Alison Durran[SUP] 2 [/SUP], Qianhan Qian[SUP] 1 [/SUP], Shabna Ummer[SUP] 1 [/SUP], Katherine Ginsbach[SUP] 1 [/SUP], Kashish Aneja[SUP] 1 [/SUP]
Affiliations
- PMID: 41630128
- DOI: 10.1080/21645515.2026.2620849
The COVID-19 pandemic brought about a unique and rapid period of global vaccine innovation. It revealed structural challenges not only in global vaccine affordability and distribution but in the liability and indemnity structures that can both impede access and affect fair outcomes for the small number of people who suffer severe side effects. This review examines vaccine injury and compensation mechanisms, including no-fault compensation schemes, aimed at addressing both the liability and indemnity concerns of developers and the compensation due those suffering severe side effects. The ultimate aim of the review is to provide a classification of systems for those countries that are considering adopting NFCS as part of their broader public health readiness and preparedness strategies.
Keywords: COVID-19; GAVI COVAX AMC; global health governance; liability; no-fault compensation schemes (NFCS); vaccine indemnity; vaccine injury; vaccine innovation.